Rocket Lab’s selloff is missing the point because the company is no longer just a Neutron timing trade. The more important shift is that RKLB is proving it can win, build, and launch for defense customers right now, and that changes the quality of the story. A company with $2.2 billion in backlog, 38.0% revenue growth, and a fresh Space Force rapid-response launch record deserves to be judged on execution momentum, not just on launch-date anxiety. We think the market is still behind that transition.
The cleanest proof is the defense pipeline turning into real program progress. Rocket Lab passed the System Requirements Review on its $816 million prime contract to build 18 missile-defense satellites for the Space Development Agency, which is exactly the kind of milestone that separates a concept stock from a defense contractor. Add the $30 million HASTE contract with Anduril for three hypersonic test launches, and this starts to look less like optionality and more like repeatable national-security revenue.
The backlog tells the same story in one number: more than $2.2 billion. That figure expanded alongside the biggest launch contract in company history, with multiple Neutron and Electron launches booked and the total launch manifest now above 70 missions. For a company that generated $601.8 million in revenue, that backlog is meaningful support for future growth, and it helps explain why the TickerSpark Score gives RKLB a 70 on Growth and an 84 on Financial Health even though profitability is still weak.
Execution is also showing up in operating reality, not just press releases. On June 19, Rocket Lab launched the second spacecraft for the Space Force’s VICTUS HAZE mission with only 16 hours and 42 minutes between notice and liftoff, setting a new tactically responsive launch record. That matters because defense customers pay for reliability and speed under pressure, and this was a public demonstration of both. The market’s reaction looks even more disconnected when sentiment is strongly positive, consensus still sits at Buy with 14 buys against 4 holds and 1 sell, and recent analyst calls have turned more constructive.
The pushback is obvious: RKLB is expensive and still unprofitable. A 72.75x price-to-sales multiple, negative 33.2% operating margin, and negative 26.9% net margin leave no room for sloppy execution, while Neutron’s delay to Q4 2026 keeps the biggest swing factor unresolved. The TickerSpark Score makes that trade-off plain enough too, with Valuation at just 20 and Profitability at 35.
The chart also says this is not a calm setup. RKLB is below both its 20-day and 50-day moving averages, RSI is 36.7, and the stock has been under distribution even after staying above its 200-day average. Insider activity does not help the optics either, with 128,000 shares sold for $14.45 million across the most recent reported sales. Even so, those are reasons for volatility, not reasons to ignore the fact that the business is becoming more strategically relevant to defense customers now.
That is why we would treat this pullback as a high-risk bullish reset, not a broken thesis. The trigger we would watch is simple: continued conversion of defense wins into visible milestones and revenue support, especially around the SDA program, HASTE launch cadence, and the next earnings report expected in early August. If Rocket Lab keeps stacking execution proof points, the market will have a harder time valuing it like a pure speculation vehicle.
Positioning still needs discipline because this is not a cheap stock and the tape is volatile. We would respect that risk, but the bigger takeaway stands: RKLB is increasingly behaving like an emerging defense prime with launch capability attached, and that is a stronger story than the selloff suggests.
